Nicholas Investment Partners LP bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 131,133 shares of the company's stock, valued at approximately $7,623,000. Nicholas Investment Partners LP owned 0.09% of Vaxcyte at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its position in Vaxcyte by 115.2% during the 1st quarter. Royal Bank of Canada now owns 29,471 shares of the company's stock worth $1,113,000 after acquiring an additional 15,774 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Vaxcyte during the first quarter valued at $219,000. Caxton Associates LLP acquired a new position in shares of Vaxcyte during the first quarter valued at $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Vaxcyte by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company's stock valued at $19,409,000 after purchasing an additional 41,034 shares in the last quarter. Finally, Cetera Investment Advisers raised its stake in shares of Vaxcyte by 13.8% during the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company's stock valued at $250,000 after purchasing an additional 932 shares in the last quarter. Institutional investors own 96.78% of the company's stock.
Insider Transactions at Vaxcyte
In other Vaxcyte news, CEO Grant Pickering sold 22,461 shares of the company's stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $52.50, for a total value of $1,179,202.50. Following the completion of the sale, the chief executive officer directly owned 474,703 shares of the company's stock, valued at approximately $24,921,907.50. This represents a 4.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the firm's stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $57.28, for a total transaction of $572,800.00. Following the transaction, the chief financial officer owned 104,395 shares of the company's stock, valued at approximately $5,979,745.60. This trade represents a 8.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 120,646 shares of company stock valued at $6,570,810 in the last three months. 3.30% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on PCVX. Zacks Research raised shares of Vaxcyte from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Wall Street Zen upgraded shares of Vaxcyte from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a research note on Monday, July 6th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Vaxcyte has a consensus rating of "Moderate Buy" and an average price target of $86.00.
Check Out Our Latest Report on Vaxcyte
Vaxcyte Stock Performance
Shares of NASDAQ PCVX opened at $61.87 on Tuesday. Vaxcyte, Inc. has a 1 year low of $29.87 and a 1 year high of $65.00. The firm has a market cap of $9.21 billion, a P/E ratio of -8.11 and a beta of 1.23. The stock has a fifty day moving average price of $56.67 and a two-hundred day moving average price of $55.84.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping analysts' consensus estimates of ($2.06) by $0.09. During the same period in the prior year, the company posted ($1.22) earnings per share. On average, research analysts predict that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
